A5027638878- CAR-T cell therapy research
- Galectins and Cancer Biology
- Macrophage Migration Inhibitory Factor
- Monoclonal and Polyclonal Antibodies Research
- Phagocytosis and Immune Regulation
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
- CRISPR and Genetic Engineering
- Viral Infectious Diseases and Gene Expression in Insects
Allogene Therapeutics (United States)
2022
CD70 is highly expressed in renal cell carcinoma (RCC), with limited expression normal tissue, making it an attractive CAR T target for immunogenic solid tumor indication. Here we generated and characterized a panel of anti-CD70 single-chain fragment variable (scFv)-based cells. Despite the on cells, production cells from subset scFvs potent vitro activity was achieved. Expression CARs masked detection cis provided protection cell-mediated fratricide. Two distinct classes were identified...
TPS6581 Background: Acute myeloid leukemia (AML) is the most common adult acute leukemia. Patients with relapsed or refractory (R/R) disease have dismal outcomes complete remission (CR) rates of 5%- 15% and median overall survival 3 to 6 months best available therapies. In addition, patients in measurable residual (MRD) poor no approved CER-1236 an autologous chimeric engulfment receptor T cell (CER-T) which fuses external domain TIM-4 intracellular domains from cells innate immune including...
To leverage complementary mechanisms for cancer cell removal, we developed a novel engineering and therapeutic strategy co-opting phagocytic clearance antigen presentation activity into T cells. We engineered chimeric engulfment receptor (CER)-1236, which combines the extracellular domain of TIM-4, recognizing "eat me" signal phosphatidylserine, with intracellular signaling domains (TLR2/TIR, CD28, CD3ζ) to enhance both TIM-4-mediated phagocytosis cytotoxic function. CER-1236 cells...
Abstract Purpose: Disruption of lipid bilayer asymmetry is a common feature observed in cancer cells and offers novel routes for therapeutic targeting. We used the natural immune receptor TIM-4 to interrogate loss plasma membrane phospholipid polarity primary acute myelogenous leukemia (AML) samples evaluated anti-leukemic activity TIM-4-L–directed T-cell therapy preclinical AML models. Experimental Design: performed FACS analysis on 33 bone marrow specimens correlated TIM-4-L expression...
<p>Supplementary materials and methods, tables, figures</p>
<p>Supplementary materials and methods, tables, figures</p>
<div>AbstractPurpose:<p>Disruption of lipid bilayer asymmetry is a common feature observed in cancer cells and offers novel routes for therapeutic targeting. We used the natural immune receptor TIM-4 to interrogate loss plasma membrane phospholipid polarity primary acute myelogenous leukemia (AML) samples evaluated anti-leukemic activity TIM-4-L–directed T-cell therapy preclinical AML models.</p>Experimental Design:<p>We performed FACS analysis on 33 bone marrow...
<div>AbstractPurpose:<p>Disruption of lipid bilayer asymmetry is a common feature observed in cancer cells and offers novel routes for therapeutic targeting. We used the natural immune receptor TIM-4 to interrogate loss plasma membrane phospholipid polarity primary acute myelogenous leukemia (AML) samples evaluated anti-leukemic activity TIM-4-L–directed T-cell therapy preclinical AML models.</p>Experimental Design:<p>We performed FACS analysis on 33 bone marrow...
<h3>Background</h3> Ovarian cancer is the most deadly gynecologic malignancy, with almost 20,000 cases diagnosed per year in US. While many patients respond to initial chemotherapy, recurs and there are limited treatment options for advanced relapsed ovarian cancer. A major hurdle deployment of engineered T cell therapies has been identification specific tumor antigens absent healthy tissue. Phosphatidylserine, ligand TIM-4 (TIM-4-L), normally sequestered on interior plasma membrane, but...
Abstract Disruption of the lipid asymmetric bilayer is a common feature observed in cancer cells. We utilized natural immune receptor TIM-4 to interrogate for loss plasma membrane phospholipid polarity primary acute myelogenous leukemia (AML) samples. performed FACs analysis 33 patients and correlated TIM-4-L expression frequency intensity with molecular disease characteristics. In normal tissues, confined internal leaflet membrane. By contrast, 86% untreated AML blasts our displayed...
Abstract CD70 is highly expressed on renal cell carcinoma (RCC), with limited normal tissue expression, making it an attractive CAR T target for immunogenic solid tumor indication. Here we generated and characterized a panel of anti-CD70 scFv-based cells. Despite the expression cells, production from subset scFvs potent in vitro activity was achieved. Expression CARs found to mask detection cis provide protection T-mediated fratricide. Two unique classes cells were identified differing...